Reading time: 11 minutes

China’s genetic testing industry has matured rapidly over the past decade — BGI, Berry Genomics, Burning Rock Biotech, Genecast, Genetron, Dian Diagnostics, and others provide tumour molecular pathology NGS, hereditary disease panels, prenatal NIPT, and related services, with technical capability comparable to mainstream Western laboratories [1]. One thing international patients must understand before anything else: China imposes strict regulation on the cross-border transfer of human genetic resources, including genomic data [2], and this directly affects whether sequencing results generated in China can be carried back to your home country and what form they can take. This article works through the categories of testing available, the regulatory framework, the process, typical costs, and how testing connects with genetic counseling.

1. Main Categories of Genetic Testing Available in China

Tumour molecular pathology:

  1. Small panels (10–50 genes): focused on key driver genes for a specific cancer type (e.g., lung cancer EGFR / ALK / ROS1)
  2. Medium panels (100–300 genes): common multi-tumour driver genes and treatment targets
  3. Large panels (500+ genes): including TMB, MSI, HRR, HRD comprehensive assessment
  4. Liquid biopsy (ctDNA): plasma cell-free DNA testing, used for recurrence monitoring and dynamic assessment
  5. WES / WGS (exome / whole genome): rare cancer, undefined-cause disease

Hereditary disease:

  1. Hereditary cancer syndrome panels (BRCA1/2, Lynch, TP53, PTEN, others)
  2. Rare disease panels (neuromuscular, metabolic, cardiovascular, renal, others)
  3. Newborn genetic screening (selected commercial panels)

Reproductive and prenatal:

  1. NIPT non-invasive prenatal testing (trisomy 21 / 18 / 13)
  2. Carrier screening (recessive genetic disease)
  3. PGT-A / PGT-M / PGT-SR (combined with IVF, see Article #53)

2. The Key Regulation: Human Genetic Resources Administration

The Regulation on the Administration of Human Genetic Resources of the People’s Republic of China took effect in 2019, with implementing rules issued by the Ministry of Justice in 2023 [2]. Core points for international patients:

  1. Performing genetic testing in a Chinese laboratory is permitted — this is a compliant medical service
  2. Cross-border transfer of genetic data and raw sequencing data is tightly regulated and may require formal approval
  3. Test reports (the interpreted output) can generally be carried back to your home country — this falls within reasonable medical service deliverables
  4. Cross-border transport of the biological samples themselves (DNA, tissue) is strictly restricted
  5. International scientific research collaboration based on Chinese patient data requires Ministry of Science and Technology filing or approval

Practical implications for international patients:

  1. As a foreign national, having genetic testing performed in China and taking the report (variants list, clinical annotation, drug recommendation) back home is the standard pathway
  2. Cross-border transfer of raw FASTQ / BAM files generally requires defined purpose and approval under the current framework
  3. If you want independent verification in your home country: retain a portion of the sample at home and re-sequence locally, rather than relying on raw data transfer

3. Genetic Counseling — How It Differs Between China and the West

Plain facts:

  1. In the US, genetic counsellor is a distinct certified profession (ABGC certification). The genetic counselling profession in China is comparatively newer, and at many hospitals the counselling function is provided by clinical geneticists supported by an assistant team
  2. Chinese centres with genetic counselling resources include PUMCH Genetic Counselling Clinic, Children’s Hospital of Fudan University, Renji Hospital Shanghai, Peking University Third Hospital, Guangzhou Women and Children’s Medical Center, and others
  3. Practical recommendation for international patients: for complex genetic questions — particularly family decision-making, reproductive planning, and insurance ethics — genetic counselling is best done in your home country, with Chinese testing as the laboratory component

4. Clinical Value of Tumour Genetic Testing (Plain Speaking)

Applications with clear evidence:

  1. Advanced lung adenocarcinoma: EGFR / ALK / ROS1 / RET / MET / KRAS / BRAF / NTRK / HER2 panel → drives targeted therapy
  2. Colorectal cancer: RAS / BRAF / MSI / HER2 → drives targeted and immunotherapy strategy
  3. Breast cancer: HER2 / BRCA / PI3K → drives therapy
  4. Melanoma: BRAF / NRAS / KIT → drives targeted therapy
  5. Ovarian cancer: BRCA / HRD → drives PARP inhibitor use
  6. Pan-cancer markers: TMB-H, MSI-H / dMMR → drives immunotherapy
  7. NTRK / RET fusions: tumour-agnostic targeted therapy

Weaker or still-developing applications:

  1. Routine “companion diagnostic” large panels for early-stage tumours — most early-stage cases do not need a large panel
  2. Healthy-individual baseline whole-genome sequencing — most findings are variants of uncertain significance (VUS) that do not inform treatment

5. Testing Providers to Consider

Clinical genetic medicine (hospital-based):

Hospital City
Peking Union Medical College Hospital, Genetic Counselling Clinic Beijing
Children’s Hospital of Fudan University, Genetics and Metabolic Disease Shanghai
Peking University Third Hospital / CITIC-Xiangya (reproductive genetics) Beijing / Changsha
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Genetics Shanghai
Guangzhou Women and Children’s Medical Center, Genetics Centre Guangzhou
Children’s Hospital of Zhejiang University, Genetics and Metabolic Disease Hangzhou

Third-party testing companies (public or large-scale):

  1. BGI Genomics
  2. Burning Rock Biotech (US-listed)
  3. Genecast
  4. Genetron (US-listed)
  5. Berry Genomics (prenatal focus)
  6. Dian Diagnostics (comprehensive)
  7. KingMed Diagnostics (comprehensive)

6. Typical Process

  1. Sample type: usually tumour tissue (FFPE block) or blood (ctDNA)
  2. Sample delivery: hospital laboratory or third-party
  3. Turnaround: 2–4 weeks
  4. Report interpretation: physician, with genetic counselling where indicated
  5. Clinical decisions: discussed with oncology or clinical genetics physician

7. Typical Costs (USD, 1 USD = 6.5 RMB)

Item Public hospital Third-party laboratory
Single-gene EGFR test 150–400 200–500
Lung cancer small panel (10 genes) 350–700 500–1,000
Solid tumour medium panel (100+ genes) 800–1,500 1,000–2,200
Solid tumour large panel (500+ genes incl. TMB / MSI / HRR) 1,500–3,500 2,000–4,500
Liquid biopsy ctDNA 600–1,500 800–2,200
Hereditary cancer panel (BRCA + Lynch and similar, 20–50 genes) 350–800 500–1,200
Whole exome (WES) 800–1,800 1,200–2,500
Whole genome (WGS) 1,500–3,500 2,000–4,500
Genetic counselling clinic visit (hospital) 80–250 —

US reference: solid tumour large panel (FoundationOne CDx and similar) typically USD 5,000–8,000 [3]; BRCA testing USD 1,500–4,000.

8. What MedCareInChina Can and Cannot Do on the Genetic Testing Pathway

Our two products are Remote Consultation and In-China Accompanied Care.

  1. Remote Consultation: USD 800 single-expert consultation. After a genetic report is issued, you can remote-consult with an oncologist or clinical geneticist to discuss results and treatment direction
  2. In-China Accompanied Care: genetic testing typically does not require the patient to travel — samples can be shipped; if you are already in China for care, accompaniment can be arranged alongside

What we do not do: we do not interpret genetic reports (clinicians or counsellors do), we do not collect samples on your behalf, we do not participate in cross-border data transfer (high compliance risk), and we do not promote any specific testing package.

9. Action Checklist

  1. Clarify the purpose of testing (treatment guidance vs risk assessment vs rare disease diagnosis)
  2. Discuss with your home-country physician whether the test is truly needed
  3. Confirm the appropriate panel through a remote consultation
  4. Ship the sample and wait for the report (2–4 weeks)
  5. The report is interpreted by a clinician, with genetic counselling where indicated
  6. For most foreign patients: the report can be carried home; raw data cross-border transfer requires careful compliance handling

Sources

[1] National Medical Products Administration of China — In-vitro diagnostic device approval records (including NGS-based assays): https://www.nmpa.gov.cn/ [2] State Council of the People’s Republic of China — Regulation on the Administration of Human Genetic Resources, and Ministry of Justice 2023 implementing rules: https://www.most.gov.cn/ [3] FoundationOne CDx — public pricing references; similar references from MSK-IMPACT / Tempus [4] National Comprehensive Cancer Network — Biomarker testing guidelines: https://www.nccn.org/ [5] American Board of Genetic Counseling — Counselor certification: https://www.abgc.net/